Management of bleeding in patients taking FXa and FIIa inhibitors

British Journal of Haematology

Volumn 160, Issue 1, 2013, Pages 1-2

  Keeling, David ^a   Cotter, Finbarr ^b  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR IIA INHIBITOR; BLOOD CLOTTING INHIBITOR; DABIGATRAN; PROTHROMBIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN INHIBITOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG; WARFARIN;

BINDING AFFINITY; BINDING SITE; BLEEDING; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEMODIALYSIS; HEMOPHILIA; HUMAN; NOTE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME;

FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS;

EID: 84870784781     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12106     Document Type: Note

References (14)

1. Bates, S.M. & Weitz, J.I. (2006) The status of new anticoagulants. British Journal of Haematology, 134, 3-19.
2. CRASH-2 (2010) Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet, 376, 23-32.
3. Eerenberg, E.S., Kamphuisen, P.W., Sijpkens, M.K., Meijers, J.C., Buller, H.R. & Levi, M. (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation, 124, 1573-1579.
4. Garcia, D., Libby, E. & Crowther, M.A. (2010) The new oral anticoagulants. Blood, 115, 15-20.
5. Hedner, U. & Lee, C.A. (2011) First 20 years with recombinant FVIIa (NovoSeven). Haemophilia, 17, e172-e182.
6. Kaatz, S., Kouides, P.A., Garcia, D.A., Spyropolous, A.C., Crowther, M., Douketis, J.D., Chan, A.K.C., James, A., Moll, S., Ortel, T.L., Van Cott, E.M. & Ansell, J. (2012) Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. American Journal of Hematology, 87(Suppl. 1), S141-S145.
7. Keeling, D., Baglin, T., Tait, C., Watson, H., Perry, D., Baglin, C., Kitchen, S. & Makris, M. (2011) Guidelines on oral anticoagulation with warfarin - fourth edition. British Journal of Haematology, 154, 311-324.
8. Levi, M., Eerenberg, E. & Kamphuisen, P.W. (2011) Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. Journal of Thrombosis and Haemostasis: JTH, 9, 1705-1712.
9. Luu, H. & Ewenstein, B. (2004) FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia, 10(Suppl. 2), 10-16.
10. Makris, M., Van Veen, J.J., Tait, R.C., Mumford, A.D., Laffan, M. & on behalf of the British Committee for Standards in Haematology (2012) Guideline on the management of bleeding in patients on antithrombotic agents. British Journal of Haematology, doi:10.1111/bjh.12107.
11. Marlu, R., Hodaj, E., Paris, A., Albaladejo, P., Crackowski, J.L. & Pernod, G. (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thrombosis and Haemostasis, 108, 217-224.
12. Turecek, P.L., Varadi, K., Gritsch, H. & Schwarz, H.P. (2004) FEIBA: mode of action. Haemophilia, 10(Suppl. 2), 3-9.
13. Warkentin, T.E., Margetts, P., Connolly, S.J., Lamy, A., Ricci, C. & Eikelboom, J.W. (2012) Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood, 119, 2172-2174.
14. Weitz, J.I. (2011) Factor Xa and thrombin as targets for new oral anticoagulants. Thrombosis Research, 127(Suppl. 2), S5-S12.